Opendata, web and dolomites

IMMUNISA SIGNED

A Next Generation Immunotherapy for Human Papilloma Virus induced Cervical Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUNISA project word cloud

Explore the words cloud of the IMMUNISA project. It provides you a very rough idea of what is the project "IMMUNISA" about.

framework    human    underdeveloped    recurrent    prevent    optimal    too    types    treatment    combination    cxca    extremely    cutting    risk    therapeutic    push    service    sme    solid    curative    premalignant    tumour    measured    hpv16    patients    papillomavirus    free    induce    pivotal    incidence    previously    proprietary    consisting    immunotherapy    oncogenic    works    biotech    prolonged    prophylactic    specialised    catapult    chemotherapy    deaths    sites    longer    proteins    care    detected    commercial    isa101b    randomised    surgery    trial    synthetic    vaccine    edge    caused    clinical    cervical    survival    shown    once    sufficiently    efficacy    careful    synergistically    274    vaccines    directed    centre    vaccination    therapy    multidisciplinary    isa101    proposes    cancer    500    global    approved    immunisa    formulated    cervisa    progression    radio    peptides    lesions    regulatory    epitopes    countries    overlapping    members    efficient    hpv    strategy    strategic    data    fast    standard    translation    infected    immune   

Project "IMMUNISA" data sheet

The following table provides information about the project.

Coordinator
KATHOLIEKE UNIVERSITEIT LEUVEN 

Organization address
address: OUDE MARKT 13
city: LEUVEN
postcode: 3000
website: www.kuleuven.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Project website https://www.isa-pharma.com/isa101-hpv16/
 Total cost 5˙999˙999 €
 EC max contribution 5˙999˙999 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2022-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) coordinator 496˙875.00
2    INC RESEARCH UK LTD UK (CAMBERLEY) participant 3˙368˙802.00
3    ISA THERAPEUTICS BV NL (LEIDEN) participant 1˙653˙009.00
4    GRANZER HEINZ ULRICH DE (MUNCHEN) participant 267˙187.00
5    TTOPSTART BV NL (UTRECHT) participant 183˙875.00
6    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 30˙250.00

Map

 Project objective

Cervical cancer (CxCa) is caused by high risk types of the human papillomavirus (a.o. HPV16). Prophylactic HPV vaccination is not the standard of care in all European countries, and where approved it is not sufficiently adopted. Once infected, these vaccines no longer prevent premalignant lesions and CxCa, which can only be treated with surgery or radio-chemotherapy. However, this is not effective in recurrent/advanced CxCa. In underdeveloped countries, CxCa is often detected when it is too late for curative treatment. With an estimated global incidence of 500.000 new cases of CxCa and 274.000 deaths per year, the need for an effective therapy is extremely high. Targeted immunotherapy is an effective approach to induce a tumour-directed immune response. Previously, members of the IMMUNISA consortium have formulated ISA101, a cancer vaccine consisting of overlapping synthetic long peptides covering all epitopes of the HPV16 oncogenic proteins. ISA101 has shown promising Phase 1 clinical trial results in patients with advanced CxCa where it works synergistically with chemotherapy. IMMUNISA now proposes the multi-centre randomised Phase 2 CervISA-2 trial; a careful assessment of the efficacy of the proprietary ISA101b therapeutic vaccine in combination with chemotherapy for the treatment of CxCa, measured by a prolonged progression free survival. A multidisciplinary collaboration between leading clinical EU sites specialised in CxCa, a partner providing strategic and operational regulatory service and a cutting-edge biotech SME will enable the optimal implementation of the CervISA-2 trial, exploitation activities and overall project dissemination. This is pivotal to catapult further development of ISA101b as a commercial vaccine and push it towards clinical implementation as fast as possible. For ISA101b, IMMUNISA will provide, 1) clinical data on the efficacy, 2) a solid exploitation strategy and 3) the regulatory framework for efficient translation to clinical use.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNISA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNISA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ENDOSCAPE (2019)

ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More  

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Read More